The study aims to investigate, through the International Prostatic Symptoms Score (IPSS) questionnaire, the non-inferiority of the therapy with the alpha-blockers+Serenoa repens combination compared to the alpha-blockers+antimuscarinic combination on storage lower urinary tract syndrome (LUTS) in patients with moderate-severe symptomatic benign prostatic hyperplasia (BPH).
Age 40-80 inclusive
Male
With moderate-to-severe LUTS from BPH according to IPSS score
Placed on AB+Serenoa repens or AB+antimuscarinics for 6 months
Prostate or bladder cancer
History of neurogenic bladder
Urinary tract abnormalities (including urethral strictures)
The study population consists of men affected by moderate-severe BPH (assessed using the IPSS questionnaire) with mixed symptoms, treated with AB + Serenoa repens or AB + antimuscarinics in the period from January 2020 to October 2025, with follow-up until March 2025.
Other
Retrospective
Not listed
DIFFERENCE IN IPSS
Difference in International Prostatic Symptoms Score (IPSS) at follow-up between the two treatment groups. IPSS min value 0 - max value 35, where: * 0-7 refers to mild symtomps; * 8-19 refers to moderate symtomps; * 20-35 refers to severe symtomps. Non-inferiority will be defined as a difference of up to 1 point in the International Prostatic Symptoms Score (IPSS) between the two groups at follow-up.
SIDE EFFECTS
Frequency of side effects in the two treatment categories
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
